Tenecteplase for Stroke at 4.5 to 24 Hours

Abstract

To the Editor: We wonder whether the TIMELESS (Thrombolysis in Imaging Eligible, Late Window Patients to Assess the Efficacy and Safety of Tenecteplase) trial (Feb. 22 issue),1 like many other trials in the field of stroke therapy, may have been underpowered. Whereas endovascular thrombectomy has a low number needed to treat for a benefit of approximately 2.6,2 other treatments for stroke have much lower effect sizes. In this trial, the adjusted common odds ratio for a 1-point improvement in the score on the modified Rankin scale at 90 days (range, 0 to 6, with higher scores indicating greater disability and .